TrialThe lancet. Diabetes & endocrinology2019

Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Bernard Zinman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.